Skip to main content
. 2022 May 18;8(20):eabn7382. doi: 10.1126/sciadv.abn7382

Fig. 6. Therapeutic efficacy in vivo.

Fig. 6.

(A) Administration schedule of RNCOs-D in the subcutaneous U87-EGFRvIII tumor model. (B) Dynamic biodistributions and (C) semiquantitative biodistributions of RNCOs and rRNCOs at different time intervals. (D) Body weight profile, (E) tumor growth curve, and (F) tumor weight after treatment with PBS, DOX, rRNCOs-D, RNSs-D, nRNCOs-D, and RNCOs-D, respectively. Data are means ± SD (n = 4). Statistical significance was determined by unpaired two-tailed Student’s t-test (*P < 0.05 and ***P < 0.001). (G) Immunohistochemical analysis for changes of EGFRvIII expression in harvested tumors followed by identical treatment in (D). Brown indicates the target protein, and blue is from the nucleus staining. Scale bar, 50 μm. (H) H&E, TUNEL, and Ki-67 analysis of tumor after the same treatments in (D). Scale bars, 100, 100, and 50 μm, respectively.